Literature DB >> 21491140

[Cancer breakthrough pain. Indications for rapidly effective opioids].

J Kessler1, H J Bardenheuer.   

Abstract

The pharmacotherapy of tumor pain has two main aims: to deliver an adequate basic analgesia using long-term retarded opioid medication and an effective treatment of tumor breakthrough pain using rapidly effective non-retarded opioids. Breakthrough pain is characterized by a sudden onset and rapid increase in the pain level and should be treated with correspondingly rapidly effective opioids. The pharmacological characteristics of previously available and routinely prescribed non-retarded opioids do not always correspond in oral galenics to the demands resulting from the definition of tumor breakthrough pain. As alternatives to these substances five different rapidly effective fentanyl preparations are now available for transmucosal administration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21491140     DOI: 10.1007/s00101-011-1868-1

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  33 in total

1.  Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Authors:  P H Coluzzi; L Schwartzberg; J D Conroy; S Charapata; M Gay; M A Busch; J Chavez; J Ashley; D Lebo; M McCracken; R K Portenoy
Journal:  Pain       Date:  2001-03       Impact factor: 6.961

2.  An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain.

Authors:  A Caraceni; R K Portenoy
Journal:  Pain       Date:  1999-09       Impact factor: 6.961

Review 3.  Nasal administration of opioids for pain management in adults.

Authors:  O Dale; R Hjortkjaer; E D Kharasch
Journal:  Acta Anaesthesiol Scand       Date:  2002-08       Impact factor: 2.105

4.  A randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries.

Authors:  Patrick J Mahar; Jamal A Rana; Christopher S Kennedy; Norman C Christopher
Journal:  Pediatr Emerg Care       Date:  2007-08       Impact factor: 1.454

5.  Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.

Authors:  Richard L Rauck; Marvin Tark; Eva Reyes; Teresa G Hayes; Anthony J Bartkowiak; David Hassman; Srinivas Nalamachu; Rob Derrick; Julian Howell
Journal:  Curr Med Res Opin       Date:  2009-12       Impact factor: 2.580

6.  Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.

Authors:  Neal E Slatkin; Fang Xie; John Messina; Thalia J Segal
Journal:  J Support Oncol       Date:  2007 Jul-Aug

7.  Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers.

Authors:  Barbara A Coda; Anita C Rudy; Sanford M Archer; Daniel P Wermeling
Journal:  Anesth Analg       Date:  2003-07       Impact factor: 5.108

Review 8.  The clinical applications of intranasal opioids.

Authors:  Katherine Shelley; Michael James Paech
Journal:  Curr Drug Deliv       Date:  2008-01       Impact factor: 2.565

9.  A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.

Authors:  S Mercadante; L Radbruch; A Davies; P Poulain; T Sitte; P Perkins; T Colberg; M A Camba
Journal:  Curr Med Res Opin       Date:  2009-11       Impact factor: 2.580

10.  Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery.

Authors:  David Foster; Richard Upton; Lona Christrup; Lars Popper
Journal:  Ann Pharmacother       Date:  2008-08-26       Impact factor: 3.154

View more
  3 in total

1.  [Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society].

Authors:  S Wirz; C H R Wiese; M Zimmermann; U Junker; E Heuser-Grannemann; M Schenk
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

Review 2.  [Breakthrough pain and short-acting opioids].

Authors:  T Beutlhauser; J Oeltjenbruns; M Schäfer
Journal:  Anaesthesist       Date:  2013-06       Impact factor: 1.041

3.  Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.

Authors:  Eva Katharina Masel; Robert Landthaler; Margit Gneist; Herbert Hans Watzke
Journal:  Support Care Cancer       Date:  2017-08-28       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.